www.Top100Medicine.com - TOP 100 MEDICAL SITES
TOP 100 MEDICAL SITES
 Main  |  Add a Site  |  FREE Content for Your Web-site  |  Bookmark this site  |  Links  |  Webmaster 
Updated Sun, August 22, 2010.
201.www.vidal.fr20000
202.www.zbmed.de19900
203.www.stronghealth.com19700
204.www.arznei-telegramm.de19700
205.www.brighamandwomens.org19400
206.www.labcorp.com19000
207.www.awfulplasticsurgery.com18800
208.www.kp.org18800
209.www.csmc.edu18700
210.omni.ac.uk18400
211.www.paris-nord-sftg.com18000
212.www.wma.net18000
213.www.medbioworld.com17200
214.www.dialyse-online.de17000
215.www.theheart.org16900
216.www.centromaderna.it16900
217.www.medical-library.org16800
218.www.pasteur-lille.fr16800
219.www.arbeit-und-gesundheit.de16700
220.www.aly-abbara.com16600
221.www.gfmer.ch16400
222.www.oecotrophologie.de16000
223.www.medicina.unibo.it16000
224.www.med.univ-angers.fr15900
225.heartdisease.about.com15800
226.www.biopsychiatry.com15600
227.www.plasticsurgery4u.com15600
228.sportsmedicine.about.com15500
229.www.minervamedica.it15500
230.www.doktoronline.no15400
231.www.hartstichting.nl14700
232.www.uas.se14700
233.www.swedish.org14500
234.www.ivi.es14500
235.medtropoli.net14500
236.www.cancerbacup.org.uk14200
237.www.medlineplus.gov14100
238.www.diseasesdatabase.com14100
239.www.lycaeum.org14000
240.www.urofrance.org13800
241.www.ospfe.it13700
242.bvs.insp.mx13500
243.www.biopsicologia.net13300
244.conganat.uninet.edu13300
245.www.itg.be13200
246.www.todoancianos.com13100
247.www.zahn-online.de12900
248.www.lumc.nl12900
249.www.cc.nih.gov12800
250.www.esculape.com12800
Pages:  1  2  3  4  5  6  7  8  9  10  11  12 
 13  14  15  16 



Subscribe to RSS feed Subscribe to Feed Burner feed Add to Del.icio.us Add to Yahoo Add to Google Add to Reddit Add to Blink Add to Meneame Add to Fark Add to Newsvine

225. heartdisease.about.com

Rating: 15800 points*
*amount mentions of word 'heartdisease.about.com' on the other websites

heartdisease.about.com

The Heart Disease and Cardiology Home Page

Description: The starting place for exploring information on heart disease and cardiology.

Most popular searches: , heartdisease.about, eartdisease.about.com, Nachrichten, heartdisese.about.com, heartdisease.bout.com, heatdisease.about.com, heardisease.about.com, heartdisease.abou.com, health care, doctor, patient, Pharmaceutical, medicine, medical information, heartdiseas.about.com, Cardiac, asthma, hertdisease.about.com, heartdiseaseabout.com, Krankenhaus, genome, heartdisease.aboutcom, heartdisease.abut.com, cholesterol, cardiology heart disease heart attack angioplasty arrhtyhmias heart failure cardiomyopathy congenital disease aortic aneurysm mitral tricuspid pulmonic aortic coronary artery disease, drug, hartdisease.about.com, heartisease.about.com, physician, family practice, health, Immunology, heartdisase.about.com, heartdsease.about.com, heartdisease.about.cm, obesity, blood pressure, vaccines, drug rehab, heartdisease.about.om, heartdisease.aout.com, heartdisease.abot.com, heartdiease.about.com, heartdiseae.about.com, heartdisease.about.co, Allergy, medical research

Google

© 2005-2010 www.Top100Medicine.com
Humana makes dental deal with Sun Life
Louisville-based Humana Inc. has formed a relationship with Sun Life Financial Inc. to offer dental-insurance plans to selected employer groups.
feeds.bizjournals.com
Baucus Will Tinker With Health Bill
Baucus said he expects to alter his health plan in a bid for support after some Democrats said the bill would impose big costs on middle-income families.
online.barrons.com
Earnings Preview: Lilly
Lilly (LLY) is expected to report Q3 earnings Wednesday, October 21 before market open, with a conference call scheduled for 9am ET. GuidanceAnalysts are looking for EPS of $1.02 on revenue of $5.41B. The consensus range is 97c-$1.12 for EPS, and $5.35B-$5.52B for revenue, according to First Call. In July, the company reported Q2 EPS of $1.12, beating analysts' expectations of $1.02 and revenue of $5.29B, which was slightly lower than consensus estimates of $5.28B. On September 14, the company reaffirmed FY09 EPS guidance of $4.20-$4.30. Investors will look forward to Cymbalta sales increasing for Q3. The sales of the anti-cancer drug Erbitux should also help revenues. Negatives for the quarter could come from currency headwinds and the impact of generic competition in the older part of Lilly's pipeline. Complete Story »
seekingalpha.com
BioMed News Bytes: Cytori, Poniard, Alkermes, Spherix, CRXX, HGSI
Mike Havrilla submits:On 11/16/09, Cytori Therapeutics (NASDAQ: CYTX) completed enrollment in a 70-patient, international breast cancer reconstruction study, RESTORE 2. The study is evaluating the use of cell-enriched fat grafting to restore functional and cosmetic deformities in women who have undergone partial mastectomy for early breast cancer. Interim data on the first 32 patients who have reached the six-month follow-up will be presented as a poster at the San Antonio Breast Cancer Symposium on 12/12/0 at 7am (CT) by Mrs. Eva Weiler-Mithoff, MD, lead investigator at the Glasgow Royal Infirmary. Cytori expects to present six-month data for 15-30 patients while final, 12-month data on all patients is expected in early 2011. The ClinicalTrials.gov identifier is NCT00616135 for the RESTORE-2 study, which is a European study designed to evaluate the transplantation of ADRC-enhanced autologous (patient-derived) fat tissue into and around breast deformities. Data from this post-marketing study will also be used to support market adoption and insurance reimbursement for the procedure.Complete Story »
seekingalpha.com
Lilly Prepares for Patent Loss in Psychosis Drug, Moves into Arthritis Market
The Burrill Report submits: Eli Lilly (LLY) has acquired global rights to Incyte's (INCY) lead mid-stage therapy for inflammatory and autoimmune diseases for $755 million. The move charts a course for Lilly's expansion into the multi-billion-dollar oral rheumatoid arthritis market, potentially helping quell investor concern about how the company will sustain its revenues once its $5 billion blockbuster Zyprexa loses patent protection in 2011. Revenue from therapies targeting autoimmune diseases, including rheumatoid arthritis, accounted for $16 billion of sales during 2008 according to IMS Health, making them the tenth largest therapeutic class globally. The Lilly agreement makes the perfect tree-topper to Incyte, which got an early gift November 25 when it struck what could turn out to be a $1 billion deal with Novartis (NVS), which licensed ex-U.S. rights for two of its investigational hematology-oncology therapies: INCB18424 for myelofibrosis and INCB28060, a potential treatment for multiple cancers. “This new alliance with Incyte reinforces Lilly's commitment to expand our presence in inflammation and autoimmunity through the development of a new class of oral anti-inflammatory therapies,” says Eiry Roberts, Lilly's vice president for autoimmune product development. For its part, Lilly will pay Incyte $90 million upfront and as much as $665 million in additional milestones and royalty payments on future sales of the drug, INCB28050 if it is successfully commercialized. It is currently being studied in a mid-stage clinical trial for rheumatoid arthritis. Incyte retains an option to co-develop its JAK1/JAK2 inhibitors with Lilly on a compound-by-compound and indication-by-indication basis, an option Incyte said it would consider exercising in the second half of 2010 at the earliest.Complete Story »
seekingalpha.com